The Composition of Oriola-KD's Nomination Committee

The Composition of Oriola-KD's Nomination Committee

ID: 342639

(Thomson Reuters ONE) -


Oriola-KD Corporation Stock Exchange Release 2 October 2014 at 9.00 a.m.

The Composition of Oriola-KD's Nomination Committee

The Board of Directors of Oriola-KD Corporation has on 1 October 2014 appointed
the following persons as members of the company's Nomination Committee:

Mr Jukka Alho
Mr Harry Brade
Mr Peter Immonen
Mr Pekka Pajamo, chairman
Mr Timo Ritakallio
Mr Into Ylppö

In accordance with the Charter of Oriola-KD Corporation's Nomination Committee,
which has been adopted by the Board of Directors, the Nomination Committee is
established by the Board of Directors with the task to prepare and present to
the Board of Directors a recommendation on a proposal to be put by the Board of
Directors to the Annual General Meeting concerning the composition and
remuneration of the Board of Directors. Members of the Nomination Committee need
not be members of the Board of Directors. The purpose of this deviation from the
Corporate Governance Code is to allow the appointment of major shareholders in
the company to the Nomination Committee and thus to ensure that their opinions
are heard well before the Annual General Meeting.


Oriola-KD Corporation
Board of Directors

For additional information, please contact:

Jukka Alho
Chairman of the Board of Directors
tel. +358 40 7367433

Petter Sandström
General Counsel, secretary to the Board of Directors
tel.  +358 10 429 5761
e-mail: petter.sandstrom(at)oriola-kd.com



Distribution
NASDAQ OMX Helsinki Ltd.
Key media

Released by:
Oriola-KD Corporation
Corporate Communications
Orionintie 5
FI-02200 Espoo, Finland
www.oriola-kd.com






This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:




(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.

Source: Oriola-KD Oyj via GlobeNewswire
[HUG#1860075]




Weitere Infos zu dieser Pressemeldung:
Unternehmensinformation / Kurzprofil:
drucken  als PDF  an Freund senden  Novartis AIN457 (secukinumab) is the first ever IL-17A inhibitor to meet primary endpoint in two Phase III studies in psoriatic arthritis ÅF AB: Financial reporting and the AGM 2015
Bereitgestellt von Benutzer: hugin
Datum: 02.10.2014 - 08:00 Uhr
Sprache: Deutsch
News-ID 342639
Anzahl Zeichen: 2472

contact information:
Town:

Espoo



Kategorie:

Business News



Diese Pressemitteilung wurde bisher 172 mal aufgerufen.


Die Pressemitteilung mit dem Titel:
"The Composition of Oriola-KD's Nomination Committee"
steht unter der journalistisch-redaktionellen Verantwortung von

Oriola-KD Oyj (Nachricht senden)

Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).


Alle Meldungen von Oriola-KD Oyj



 

Werbung



Sponsoren

foodir.org The food directory für Deutschland
News zu Snacks finden Sie auf Snackeo.
Informationen für Feinsnacker finden Sie hier.

Firmenverzeichniss

Firmen die firmenpresse für ihre Pressearbeit erfolgreich nutzen
1 2 3 4 5 6 7 8 9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z